跳至主要内容
临床试验/NCT00226772
NCT00226772已完成3 期

Double-Blind, Multicenter Phase 3 Study Comparing the Efficacy and Safety of OMS103HP With Vehicle in Patients Undergoing Autograft ACL Reconstruction

Omeros Corporation18 个研究点 分布在 2 个国家目标入组 326 人开始时间: 2005年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
326
试验地点
18
主要终点
Improvement in knee function

研究概览

简要总结

The anterior cruciate ligament (ACL) is an important stabilizer of the knee. Orthopedic surgeons replace the torn ligament during ACL reconstruction surgery. Surgical trauma initiates an acute inflammatory response, including swelling and pain, that leads to restricted joint motion and loss of function. OMS103HP was designed to deliver targeted therapeutic agents directly to the surgical site during the arthroscopic procedure to inhibit inflammation and pain before they can begin.

The purpose of this study is to assess the effectiveness and safety of OMS103HP in improving knee function following ACL reconstruction using a hamstring autograft. Secondary benefits being evaluated include reduced postoperative pain, improvement in knee range of motion, and earlier return to work.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
15 Years 至 65 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 15 - 65 years of age
  • In good general health with an ACL tear that occurred from 2 weeks to 18 months prior to the day of arthroscopic surgery
  • Undergoing primary unilateral ACL reconstruction using a medial hamstring (semitendinosus and gracilis) autograft
  • Able to participate in the study rehabilitation protocol
  • and other inclusion criteria

排除标准

  • Allergies to any of the individual ingredients in OMS103HP
  • Taking medications with the same activities as that of the active ingredients in OMS103HP for defined time intervals prior to and after surgery
  • Associated knee injuries likely to interfere with evaluation of the study drug
  • and other exclusion criteria

研究组 & 干预措施

OMS103HP irrigation solution

Experimental

Drug

干预措施: OMS103HP (Drug)

vehicle irrigation solution

Placebo Comparator

Vehicle

干预措施: Vehicle (Drug)

结局指标

主要结局

Improvement in knee function

时间窗: 30 days

次要结局

  • Decreased pain(30 days)
  • Improved range of motion(30 days)
  • Earlier return to work(30 days)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (18)

Loading locations...

相似试验